



OraSure Technologies Appoints New Chief Science Officer

April 15, 2016

Michael Reed, Ph.D. named Senior Vice President of Research and Development and Chief Science Officer

BETHLEHEM, Pa., April 15, 2016 (GLOBE NEWSWIRE) -- [OraSure Technologies, Inc.](http://www.orasure.com) (NASDAQ:OSUR) announced today that Michael Reed, Ph.D. has been named as the Company's Senior Vice President of Research and Development and Chief Science Officer. He will begin working at the Company on April 18, 2016.

Dr. Reed brings to OraSure Technologies more than 20 years of experience in life sciences and diagnostics research and development across an extensive array of disciplines including globally regulated IVD development and commercialization of molecular and cellular applications and systems. He joins OraSure after having spent the last eight years as part of the management team at Beckman Coulter, a global diagnostics and life sciences company within the Danaher Corporation.

At Beckman Coulter, Dr. Reed served in a variety of leadership positions including Director of Global Assay and Applications Development for the Beckman Coulter Life Science business encompassing flow cytometry, genomics and capillary electrophoresis reagent development and Director of Scientific Affairs for the Cellular Analysis Business Group, including flow cytometry and hematology reagent research and development, and clinical affairs. Under his leadership, the Company launched and commercialized over 300 products globally across multiple disciplines.

Prior to his work at Beckman Coulter, Dr. Reed served as Director of Product Development with Osmetech Molecular Diagnostics where he led the effort to develop two U.S. FDA 510K cleared IVD systems for cystic fibrosis genotyping and a pharmacogenetics test to guide warfarin dosing. He also worked at the predecessor company – Clinical Micro Sensors.

"Mike will be a valuable addition to our senior management team and we will benefit from his global leadership in research and development and specifically his expertise in regulated assay development, genomics and molecular diagnostics," stated Douglas A. Michels, President and CEO of OraSure Technologies.

Dr. Reed received a Ph.D. degree in Biochemistry from the University of Adelaide (Australia) and a BSc. in Biochemistry from The Australian National University (Canberra, Australia). He conducted post-doctoral research at the Beckman Research Institute at the City of Hope in Duarte, California.

About OraSure Technologies

[OraSure Technologies](http://www.orasure.com) is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.

For more information on OraSure Technologies, please visit www.orasure.com.

Investor Contact:

Ronald H. Spair
Chief Financial Officer
(610) 882-1820
investorinfo@orasure.com

Media Contact:

Ron Ticho
SVP, Corporate Communications
(484) 353-1575
media@orasure.com



OraSure Technologies